Oxford Hospitals Team Secures £520,000 for Haemophilia Ankle Arthritis Treatment Research
National funding awarded to study the use of intra-articular hyaluronic acid to improve pain and function for patients with haemophilic arthropathy.
By Laura Medhurst
••2 min read
AI
Generic image of a medical syringe and a vial with a clear fluid, with blurred anatomical diagrams of a human ankle joint in the background.
A team from Oxford University Hospitals (OUH) has secured £520,000 in national funding to investigate a novel treatment for ankle arthritis caused by haemophilia.
Dr Nicola Curry, Consultant Haematologist, and Steph Taylor, Senior Haemophilia Physiotherapist, both based at OUH’s Oxford Haemophilia and Thrombosis Centre, will lead a multicentre clinical trial funded by the National Institute for Health and Care Research (NIHR). The research will explore whether intra-articular hyaluronic acid, sometimes referred to as ‘liquid cartilage’, can improve treatment outcomes for patients suffering from haemophilic arthropathy.
Haemophilia causes repeated bleeding into joints, leading to irreversible damage known as haemophilic arthropathy. The ankle is the most commonly affected joint, with a significant proportion of individuals experiencing damage by the age of 30. The debilitating pain associated with this condition severely impacts patients' lives, and existing treatments are limited due to the unique needs of haemophilia patients.
Building on promising results from a 2023 pilot study, which indicated that hyaluronic acid reduced pain and improved ankle function, the new trial will be a larger, placebo-controlled study across the UK. The research, developed with strong patient support, aims to definitively determine if hyaluronic acid can alleviate pain, enhance ankle function, and improve the overall quality of life for those affected.
“
"Steph and I are delighted to have support from the NIHR for this trial. We were asked by our patients in 2018 to investigate better treatments for ankle arthropathy. To be able to deliver this national trial is exciting, as we will be able to provide important answers to our patients. It has been, and will continue to be, a truly patient-designed clinical trial."
“
"Our study has the potential to open new avenues for routine therapy for our haemophilia patient group."
Hyaluronic acid is a naturally occurring substance in the body's joints and is sometimes used to treat osteoarthritis-related knee pain. The funding from the NIHR's Research for Patient Benefit (RfPB) programme is expected to pave the way for new routine therapies for the haemophilia patient group.